Lumen News

Lumen News image

Lumen News image

Ultra-Rapid, Low-Cost Neutralizing Antibody Therapeutic for COVID-19

Ultra-Rapid, Low-Cost Neutralizing Antibody Therapeutic for COVID-19

March 18, 2021

Beyond the lung: treating the GI symptoms of Covid-19

Beyond the lung: treating the GI symptoms of Covid-19

February 16, 2021

High Impact Drugs at Dirt Cheap Cost

High Impact Drugs at Dirt Cheap Cost

February 12, 2021

CARB-X awards $5.3M to Lumen for diarrheal disease research, development

CARB-X awards $5.3M to Lumen for diarrheal disease research, development

February 12, 2021

Lumen bags U.S. grant for GI-focused COVID-19 antibody cocktail

Lumen bags U.S. grant for GI-focused COVID-19 antibody cocktail

November 23, 2020

Lumen Bioscience reels in $16M Series B to democratize biologics

Lumen Bioscience reels in $16M Series B to democratize biologics

November 23, 2020

With a $4M federal grant, Lumen jumps into the Covid-19 treatment race

With a $4M federal grant, Lumen jumps into the Covid-19 treatment race

November 23, 2020

Q and A with Lumen: using spirulina to manufacture Covid-19 antibodies

Q and A with Lumen: using spirulina to manufacture Covid-19 antibodies

November 11, 2020

Camelid Nanobodies Poised to Revolutionize Antibody Therapeutics

Camelid Nanobodies Poised to Revolutionize Antibody Therapeutics

August 26, 2020